Identification

Name
Ganciclovir
Accession Number
DB01004  (APRD00263, EXPT01540)
Type
Small Molecule
Groups
Approved, Investigational
Description

An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. [PubChem]

Structure
Thumb
Synonyms
  • 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
  • 2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
  • 2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
  • 2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
  • 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
  • 2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
  • 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
  • 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
  • GA2
  • Ganciclovir
  • Ganciclovirum
  • Gancyclovir
External IDs
BW 759U / BW-759U / RS-21592
Product Ingredients
IngredientUNIICASInChI Key
Ganciclovir Sodium02L083W284107910-75-8JJICLMJFIKGAAU-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CytovenePowder, for solution500 mgIntravenousHoffmann La Roche1995-12-31Not applicableCanada
Cytovene - Cap 250mgCapsule250 mgOralHoffmann La Roche1995-12-312007-08-02Canada
Cytovene Inj 500mg/vialPowder, for solution500 mgIntravenousSyntex Inc.1990-12-311996-09-30Canada
Cytovene IVInjection, powder, lyophilized, for solution500 mg/10mLIntravenousGenentech, Inc.1989-06-23Not applicableUs
Cytovene, 500 mgCapsule500 mgOralHoffmann La Roche2000-01-142007-08-02Canada
GanciclovirInjection, solution2 mg/mLIntravenousExela Pharma Sciences, Llc.2017-02-28Not applicableUs
Ganciclovir for InjectionPowder, for solution500 mgIntravenousFresenius Kabi2014-04-08Not applicableCanada
Ganciclovir for Injection USPPowder, for solution500 mgIntravenousAuro Pharma IncNot applicableNot applicableCanada
Vitrasert, Intravitreal ImplantImplant4.5 mgIntravitrealBausch & Lomb Inc1998-03-252008-07-28Canada
ZirganGel1.5 mg/gOphthalmicBauch & Lomb Incorporated2010-04-30Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GanciclovirCapsule250 mg/1OralRanbaxy Inc.2003-08-27Not applicableUs
GanciclovirInjection, solution500 mg/10mLIntravenousPharmascience Inc.2018-03-19Not applicableUs
GanciclovirInjection, powder, lyophilized, for solution500 mg/10mLIntravenousPar Pharmaceutical2017-03-31Not applicableUs
GanciclovirInjection, solution50 mg/mLIntravenousSagent Pharmaceuticals2018-02-15Not applicableUs
GanciclovirCapsule500 mg/1OralRanbaxy Inc.2003-08-27Not applicableUs
GanciclovirInjection, powder, lyophilized, for solution500 mg/10mLIntravenousFresenius Kabi2010-06-28Not applicableUs
GanciclovirGel1.5 mg/gOphthalmicAmici Pharmaceuticals Llc2017-09-08Not applicableUs
International/Other Brands
Cytovene / Vitrasert
Categories
UNII
P9G3CKZ4P5
CAS number
82410-32-0
Weight
Average: 255.2306
Monoisotopic: 255.096753929
Chemical Formula
C9H13N5O4
InChI Key
IRSCQMHQWWYFCW-UHFFFAOYSA-N
InChI
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
IUPAC Name
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-1H-purin-6-one
SMILES
NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1

Pharmacology

Indication

For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions
Pharmacodynamics

Ganciclovir is a synthetic nucleoside analogue of 2'-deoxyguanosine that inhibits replication of herpes viruses both in vitro and in vivo. Sensitive human viruses include cytomegalovirus (CMV), herpes simplex virus -1 and -2 (HSV-1, HSV-2), Epstein-Barr virus (EBV) and varicella zoster virus (VZV), however clinical studies have been limited to assessment of efficacy in patients with CMV infection. Ganciclovir is a prodrug that is structurally similar to acyclovir. It inhibits virus replication by its encorporation into viral DNA. This encorporation inhibits dATP and leads to defective DNA, ceasing or retarding the viral machinery required to spread the virus to other cells.

Mechanism of action

Ganciclovir's antiviral activity inhibits virus replication. This inhibitory action is highly selective as the drug must be converted to the active form by a virus-encoded cellular enzyme, thymidine kinase (TK). TK catalyzes phosphorylation of ganciclovir to the monophosphate, which is then subsequently converted into the diphosphate by cellular guanylate kinase and into the triphosphate by a number of cellular enzymes. In vitro, ganciclovir triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, ganciclovir triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed.

TargetActionsOrganism
ADNA polymerase catalytic subunit
inhibitor
HHV-1
ADNA
incorporation into and destabilization
Human
AThymidine kinase
inducer
HHV-1
Absorption

Poorly absorbed systemically following oral administration. Bioavailability under fasting conditions is approximately 5%, and when administered with food, 6 to 9% (about 30% with a fatty meal).

Volume of distribution
  • 0.74 ± 0.15 L/kg
Protein binding

1 to 2%

Metabolism

Little to no metabolism, about 90% of plasma ganciclovir is eliminated unchanged in the urine.

Route of elimination

Renal excretion of unchanged drug by glomerular filtration and active tubular secretion is the major route of elimination of ganciclovir.

Half life

2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).

Clearance
  • 128 +/- 63 mL/min [Patients with Renal Impairment (Clcr=50-79 mL/min)]
  • 57+/- 8 mL/min [Patients with Renal Impairment (Clcr=25-49 mL/min)]
  • 30 +/- 13 mL/min [Patients with Renal Impairment (Clcr<25 mL/min)]
  • 4.7+/- 2.2 mL/min/kg [pediatric patients, aged 9 months to 12 years]
Toxicity

Oral, mouse LD50: > 2g/kg. Intravenous, dog LD50: > 150mg/kg. Symptoms of overdose include irreversible pancytopenia, worsening GI symptoms, and acute renal failure. Suspected cancer agent.

Affected organisms
  • Human Herpes Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Ganciclovir.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Ganciclovir.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Ganciclovir.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Ganciclovir.Experimental, Illicit
6-Deoxyerythronolide BThe metabolism of Ganciclovir can be decreased when combined with 6-Deoxyerythronolide B.Experimental
7-Nitroindazole7-Nitroindazole may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbacavirThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Abacavir.Approved, Investigational
AbirateroneThe serum concentration of Ganciclovir can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Ganciclovir.Approved, Investigational
AcetazolamideAcetazolamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AdalimumabThe serum concentration of Ganciclovir can be decreased when it is combined with Adalimumab.Approved
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Ganciclovir.Approved, Investigational
AdinazolamThe therapeutic efficacy of Adinazolam can be decreased when used in combination with Ganciclovir.Approved
Albinterferon Alfa-2BThe metabolism of Ganciclovir can be decreased when combined with Albinterferon Alfa-2B.Investigational
AllopurinolThe serum concentration of Ganciclovir can be increased when it is combined with Allopurinol.Approved
AlprazolamThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Ganciclovir.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Alprenolol is combined with Ganciclovir.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Aluminium clofibrate.Experimental
AmobarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Amobarbital.Approved, Illicit
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Ganciclovir.Approved, Illicit, Investigational
Amphotericin BThe metabolism of Ganciclovir can be decreased when combined with Amphotericin B.Approved, Investigational
AtenololThe therapeutic efficacy of Ganciclovir can be decreased when used in combination with Atenolol.Approved
AtorvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Atorvastatin.Approved
AVE9633The metabolism of Ganciclovir can be decreased when combined with AVE9633.Investigational
BarbexacloneThe serum concentration of Ganciclovir can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Barbital.Illicit
BeclamideBeclamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ganciclovir.Approved, Illicit
BenzylthiouracilThe serum concentration of Ganciclovir can be increased when it is combined with Benzylthiouracil.Experimental
BesifloxacinThe metabolism of Ganciclovir can be decreased when combined with Besifloxacin.Approved
BetaxololThe therapeutic efficacy of Ganciclovir can be decreased when used in combination with Betaxolol.Approved, Investigational
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Bezafibrate.Approved, Investigational
BisoprololThe therapeutic efficacy of Ganciclovir can be decreased when used in combination with Bisoprolol.Approved
BopindololThe risk or severity of adverse effects can be increased when Bopindolol is combined with Ganciclovir.Approved
Brefeldin AThe metabolism of Ganciclovir can be decreased when combined with Brefeldin A.Experimental
BrivaracetamBrivaracetam may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
BromazepamThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit, Investigational
BrotizolamThe therapeutic efficacy of Brotizolam can be decreased when used in combination with Ganciclovir.Approved, Investigational, Withdrawn
Bryostatin 1The metabolism of Ganciclovir can be decreased when combined with Bryostatin 1.Investigational
BucindololThe risk or severity of adverse effects can be increased when Bucindolol is combined with Ganciclovir.Investigational
BupranololThe risk or severity of adverse effects can be increased when Bupranolol is combined with Ganciclovir.Approved
CaffeineThe metabolism of Ganciclovir can be decreased when combined with Caffeine.Approved
CamazepamThe therapeutic efficacy of Camazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
CandicidinThe metabolism of Ganciclovir can be decreased when combined with Candicidin.Withdrawn
CannabidivarinCannabidivarin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CarbamazepineThe serum concentration of Ganciclovir can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Ganciclovir can be increased when it is combined with Carbimazole.Approved, Investigational
CarbomycinThe metabolism of Ganciclovir can be decreased when combined with Carbomycin.Vet Approved
CarisbamateCarisbamate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Ganciclovir.Approved
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Ganciclovir.Approved, Investigational
Cepeginterferon alfa-2BThe metabolism of Ganciclovir can be decreased when combined with Cepeginterferon alfa-2B.Investigational
CerivastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Cerivastatin.Approved, Withdrawn
CethromycinThe metabolism of Ganciclovir can be decreased when combined with Cethromycin.Investigational
ChlordiazepoxideThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Ganciclovir.Approved, Illicit, Investigational
ChlorotrianiseneThe serum concentration of Ganciclovir can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Ganciclovir.Illicit, Withdrawn
CimetidineThe metabolism of Ganciclovir can be decreased when combined with Cimetidine.Approved, Investigational
CinolazepamThe therapeutic efficacy of Cinolazepam can be decreased when used in combination with Ganciclovir.Approved
CinoxacinThe metabolism of Ganciclovir can be decreased when combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe serum concentration of Ganciclovir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Ganciclovir can be decreased when combined with Clarithromycin.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Ganciclovir.Approved, Investigational, Vet Approved
ClobazamThe therapeutic efficacy of Clobazam can be decreased when used in combination with Ganciclovir.Approved, Illicit
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Clofibride.Experimental
clomethiazoleclomethiazole may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
CloranololThe risk or severity of adverse effects can be increased when Cloranolol is combined with Ganciclovir.Experimental
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Ganciclovir.Approved, Illicit
ClotiazepamThe therapeutic efficacy of Clotiazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
CloxazolamThe therapeutic efficacy of Cloxazolam can be decreased when used in combination with Ganciclovir.Approved, Investigational
Coltuximab ravtansineThe metabolism of Ganciclovir can be decreased when combined with Coltuximab ravtansine.Investigational
Conjugated estrogensThe serum concentration of Ganciclovir can be increased when it is combined with Conjugated estrogens.Approved
DelorazepamThe therapeutic efficacy of Delorazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit, Investigational
DeramciclaneDeramciclane may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Ganciclovir.Approved, Illicit
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit, Investigational, Vet Approved
DibromotyrosineThe serum concentration of Ganciclovir can be increased when it is combined with Dibromotyrosine.Experimental
DidanosineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Didanosine.Approved
DienestrolThe serum concentration of Ganciclovir can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylpropionThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Ganciclovir.Approved, Illicit
DiethylstilbestrolThe serum concentration of Ganciclovir can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifloxacinThe metabolism of Ganciclovir can be decreased when combined with Difloxacin.Vet Approved
DirithromycinThe metabolism of Ganciclovir can be decreased when combined with Dirithromycin.Approved, Investigational
DisulfiramThe serum concentration of Ganciclovir can be increased when it is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Ganciclovir.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Ganciclovir.Approved
DoramectinThe metabolism of Ganciclovir can be decreased when combined with Doramectin.Vet Approved
DoxefazepamThe therapeutic efficacy of Doxefazepam can be decreased when used in combination with Ganciclovir.Experimental
DoxofyllineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Doxofylline.Approved, Investigational
EmtricitabineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine.Approved, Investigational
EnoxacinThe metabolism of Ganciclovir can be decreased when combined with Enoxacin.Approved, Investigational
EntecavirThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Entecavir.Approved, Investigational
EpanololThe risk or severity of adverse effects can be increased when Epanolol is combined with Ganciclovir.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Ganciclovir.Approved
EpimestrolThe serum concentration of Ganciclovir can be increased when it is combined with Epimestrol.Experimental
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Ganciclovir.Approved, Vet Approved
EpofolateThe metabolism of Ganciclovir can be decreased when combined with Epofolate.Investigational
Epothilone DThe metabolism of Ganciclovir can be decreased when combined with Epothilone D.Experimental, Investigational
EprinomectinThe metabolism of Ganciclovir can be decreased when combined with Eprinomectin.Vet Approved
EquolThe serum concentration of Ganciclovir can be increased when it is combined with Equol.Investigational
ErythromycinThe metabolism of Ganciclovir can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EslicarbazepineEslicarbazepine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
Eslicarbazepine acetateEslicarbazepine acetate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
EsmololThe therapeutic efficacy of Ganciclovir can be decreased when used in combination with Esmolol.Approved
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Ganciclovir.Approved, Illicit
EstradiolThe excretion of Estradiol can be decreased when combined with Ganciclovir.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Ganciclovir can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Ganciclovir can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Ganciclovir can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Ganciclovir can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Ganciclovir can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Ganciclovir can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Ganciclovir can be increased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Ganciclovir can be increased when it is combined with Estrone sulfate.Approved
EthadioneEthadione may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
Ethinyl EstradiolThe serum concentration of Ganciclovir can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideEthosuximide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
EthotoinEthotoin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
Ethyl loflazepateThe therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Ganciclovir.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Ganciclovir.Withdrawn
EtiracetamEtiracetam may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
EtizolamThe therapeutic efficacy of Etizolam can be decreased when used in combination with Ganciclovir.Approved
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Etofibrate.Approved
EverolimusThe metabolism of Ganciclovir can be decreased when combined with Everolimus.Approved
EzogabineEzogabine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
FebuxostatThe serum concentration of the active metabolites of Ganciclovir can be increased when Ganciclovir is used in combination with Febuxostat.Approved
FelbamateFelbamate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Fenofibric acid.Approved
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Ganciclovir.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Fenozolone is combined with Ganciclovir.Experimental
FleroxacinThe metabolism of Ganciclovir can be decreased when combined with Fleroxacin.Approved
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
FlumequineThe metabolism of Ganciclovir can be decreased when combined with Flumequine.Withdrawn
FlunarizineFlunarizine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
FlunitrazepamThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
FlurazepamThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit, Investigational
FlurithromycinThe metabolism of Ganciclovir can be decreased when combined with Flurithromycin.Experimental
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ganciclovir can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of hypokalemia can be increased when Ganciclovir is combined with Formoterol.Approved, Investigational
FosphenytoinThe serum concentration of Ganciclovir can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinGabapentin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
GaboxadolGaboxadol may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
GarenoxacinThe metabolism of Ganciclovir can be decreased when combined with Garenoxacin.Investigational
GatifloxacinThe metabolism of Ganciclovir can be decreased when combined with Gatifloxacin.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Gemfibrozil.Approved
GemifloxacinThe metabolism of Ganciclovir can be decreased when combined with Gemifloxacin.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Ganciclovir.Experimental
GPI-1485The metabolism of Ganciclovir can be decreased when combined with GPI-1485.Investigational
GrepafloxacinThe metabolism of Ganciclovir can be decreased when combined with Grepafloxacin.Approved, Investigational, Withdrawn
HalazepamThe therapeutic efficacy of Halazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit, Withdrawn
HexestrolThe serum concentration of Ganciclovir can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Hexobarbital.Approved
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Ganciclovir.Approved
IfenprodilIfenprodil may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Withdrawn
ImipenemThe risk or severity of generalized seizure can be increased when Ganciclovir is combined with Imipenem.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Indacaterol.Approved
Interferon Alfa-2a, RecombinantThe metabolism of Ganciclovir can be decreased when combined with Interferon Alfa-2a, Recombinant.Approved, Investigational
Interferon Alfa-2b, RecombinantThe metabolism of Ganciclovir can be decreased when combined with Interferon Alfa-2b, Recombinant.Approved
Interferon alfa-n1The metabolism of Ganciclovir can be decreased when combined with Interferon alfa-n1.Approved, Investigational
Interferon alfa-n3The metabolism of Ganciclovir can be decreased when combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The metabolism of Ganciclovir can be decreased when combined with Interferon alfacon-1.Approved, Investigational
Interferon beta-1aThe metabolism of Ganciclovir can be decreased when combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe metabolism of Ganciclovir can be decreased when combined with Interferon beta-1b.Approved
Interferon gamma-1bThe metabolism of Ganciclovir can be decreased when combined with Interferon gamma-1b.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Ganciclovir.Approved
IsoniazidThe serum concentration of Ganciclovir can be increased when it is combined with Isoniazid.Approved, Investigational
IsoprenalineThe serum concentration of Ganciclovir can be decreased when it is combined with Isoprenaline.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Ganciclovir.Approved, Withdrawn
IvermectinThe metabolism of Ganciclovir can be decreased when combined with Ivermectin.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ganciclovir can be decreased when combined with Ixabepilone.Approved, Investigational
JosamycinThe metabolism of Ganciclovir can be decreased when combined with Josamycin.Approved, Investigational
KetazolamThe therapeutic efficacy of Ketazolam can be decreased when used in combination with Ganciclovir.Approved
KitasamycinThe metabolism of Ganciclovir can be decreased when combined with Kitasamycin.Experimental
KOS-1584The metabolism of Ganciclovir can be decreased when combined with KOS-1584.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Ganciclovir.Approved
LacosamideLacosamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
LamivudineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Lamivudine.Approved, Investigational
LamotrigineLamotrigine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LevetiracetamLevetiracetam may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LevofloxacinThe metabolism of Ganciclovir can be decreased when combined with Levofloxacin.Approved, Investigational
LevothyroxineThe metabolism of Ganciclovir can be increased when combined with Levothyroxine.Approved
LidocaineThe metabolism of Ganciclovir can be decreased when combined with Lidocaine.Approved, Vet Approved
LiothyronineThe metabolism of Ganciclovir can be increased when combined with Liothyronine.Approved, Vet Approved
LiotrixThe metabolism of Ganciclovir can be increased when combined with Liotrix.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Ganciclovir.Approved, Investigational
Lithium cationThe serum concentration of Lithium cation can be decreased when it is combined with Ganciclovir.Experimental
LomefloxacinThe metabolism of Ganciclovir can be decreased when combined with Lomefloxacin.Approved, Investigational
LoprazolamThe therapeutic efficacy of Loprazolam can be decreased when used in combination with Ganciclovir.Experimental
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Ganciclovir.Approved
LormetazepamThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Ganciclovir.Approved
Lorvotuzumab mertansineThe metabolism of Ganciclovir can be decreased when combined with Lorvotuzumab mertansine.Investigational
LovastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Lovastatin.Approved, Investigational
Magnesium sulfateMagnesium sulfate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
MedazepamThe therapeutic efficacy of Medazepam can be decreased when used in combination with Ganciclovir.Experimental
MefenorexThe risk or severity of adverse effects can be increased when Mefenorex is combined with Ganciclovir.Experimental
MepartricinThe metabolism of Ganciclovir can be decreased when combined with Mepartricin.Experimental
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Ganciclovir.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Ganciclovir.Approved
MephenytoinMephenytoin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational, Withdrawn
MepindololThe risk or severity of adverse effects can be increased when Mepindolol is combined with Ganciclovir.Experimental
MestranolThe serum concentration of Ganciclovir can be increased when it is combined with Mestranol.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Ganciclovir.Approved, Investigational
MethallenestrilThe serum concentration of Ganciclovir can be increased when it is combined with Methallenestril.Experimental
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Ganciclovir.Approved, Illicit
MetharbitalMetharbital may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Withdrawn
MethimazoleThe serum concentration of Ganciclovir can be increased when it is combined with Methimazole.Approved
MethohexitalThe serum concentration of Ganciclovir can be decreased when it is combined with Methohexital.Approved
MethotrexateThe serum concentration of Ganciclovir can be increased when it is combined with Methotrexate.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Ganciclovir.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Ganciclovir.Experimental
MethsuximideMethsuximide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
MethylphenobarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Methylphenobarbital.Approved
MethylthiouracilThe serum concentration of Ganciclovir can be increased when it is combined with Methylthiouracil.Experimental
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Ganciclovir.Approved, Investigational
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Mevastatin.Experimental
MexiletineThe metabolism of Ganciclovir can be decreased when combined with Mexiletine.Approved, Investigational
MidazolamThe therapeutic efficacy of Midazolam can be decreased when used in combination with Ganciclovir.Approved, Illicit
MidecamycinThe metabolism of Ganciclovir can be decreased when combined with Midecamycin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Ganciclovir.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Ganciclovir.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Ganciclovir can be increased when it is combined with Midostaurin.Approved, Investigational
MiocamycinThe metabolism of Ganciclovir can be decreased when combined with Miocamycin.Experimental
Mirvetuximab SoravtansineThe metabolism of Ganciclovir can be decreased when combined with Mirvetuximab Soravtansine.Investigational
MitemcinalThe metabolism of Ganciclovir can be decreased when combined with Mitemcinal.Investigational
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Ganciclovir.Experimental, Illicit
MoxestrolThe serum concentration of Ganciclovir can be increased when it is combined with Moxestrol.Experimental
MoxifloxacinThe metabolism of Ganciclovir can be decreased when combined with Moxifloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid.Approved
Nalidixic AcidThe metabolism of Ganciclovir can be decreased when combined with Nalidixic Acid.Approved, Investigational
NatamycinThe metabolism of Ganciclovir can be decreased when combined with Natamycin.Approved
Natural alpha interferonThe metabolism of Ganciclovir can be decreased when combined with Natural alpha interferon.Approved, Investigational
NebivololThe therapeutic efficacy of Ganciclovir can be decreased when used in combination with Nebivolol.Approved, Investigational
NemonoxacinThe metabolism of Ganciclovir can be decreased when combined with Nemonoxacin.Investigational
NeocitrullamonNeocitrullamon may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Ganciclovir.Approved
NordazepamThe therapeutic efficacy of Nordazepam can be decreased when used in combination with Ganciclovir.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Ganciclovir.Approved
NorfloxacinThe metabolism of Ganciclovir can be decreased when combined with Norfloxacin.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Ganciclovir.Approved
NystatinThe metabolism of Ganciclovir can be decreased when combined with Nystatin.Approved, Vet Approved
OfloxacinThe metabolism of Ganciclovir can be decreased when combined with Ofloxacin.Approved
OleandomycinThe metabolism of Ganciclovir can be decreased when combined with Oleandomycin.Vet Approved
OlodaterolGanciclovir may increase the hyperkalemic activities of Olodaterol.Approved
OrbifloxacinThe metabolism of Ganciclovir can be decreased when combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Ganciclovir.Approved
OxazepamThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Ganciclovir.Approved
OxcarbazepineOxcarbazepine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
Oxolinic acidThe metabolism of Ganciclovir can be decreased when combined with Oxolinic acid.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ganciclovir.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ganciclovir.Approved, Investigational
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Ganciclovir.Approved
ParaldehydeParaldehyde may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ParamethadioneParamethadione may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PatupiloneThe metabolism of Ganciclovir can be decreased when combined with Patupilone.Experimental, Investigational
PazufloxacinThe metabolism of Ganciclovir can be decreased when combined with Pazufloxacin.Investigational
PefloxacinThe metabolism of Ganciclovir can be decreased when combined with Pefloxacin.Approved
Peginterferon alfa-2aThe metabolism of Ganciclovir can be decreased when combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe metabolism of Ganciclovir can be decreased when combined with Peginterferon alfa-2b.Approved
Peginterferon beta-1aThe metabolism of Ganciclovir can be decreased when combined with Peginterferon beta-1a.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Ganciclovir.Approved, Investigational
PentobarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineThe serum concentration of Ganciclovir can be increased when it is combined with Pentoxifylline.Approved, Investigational
PerampanelPerampanel may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PhenacemidePhenacemide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PheneturidePheneturide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PhenibutPhenibut may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Ganciclovir.Approved, Illicit
PhenobarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhensuximidePhensuximide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Ganciclovir.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Ganciclovir.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Ganciclovir.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Ganciclovir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe metabolism of Ganciclovir can be decreased when combined with Pimecrolimus.Approved, Investigational
PinazepamThe therapeutic efficacy of Pinazepam can be decreased when used in combination with Ganciclovir.Experimental
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Ganciclovir.Approved, Investigational
Pipemidic acidThe metabolism of Ganciclovir can be decreased when combined with Pipemidic acid.Experimental
Piromidic acidThe metabolism of Ganciclovir can be decreased when combined with Piromidic acid.Experimental
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Pitavastatin.Approved
Polyestradiol phosphateThe serum concentration of Ganciclovir can be increased when it is combined with Polyestradiol phosphate.Approved
Potassium IodideThe serum concentration of Ganciclovir can be increased when it is combined with Potassium Iodide.Approved
Potassium perchlorateThe serum concentration of Ganciclovir can be increased when it is combined with Potassium perchlorate.Approved, Investigational
PravastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Pravastatin.Approved
PrazepamThe therapeutic efficacy of Prazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
PregabalinPregabalin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Illicit, Investigational
PrenalterolThe risk or severity of adverse effects can be increased when Prenalterol is combined with Ganciclovir.Experimental
PrimidoneThe serum concentration of Ganciclovir can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ganciclovir can be increased when it is combined with Probenecid.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Ganciclovir.Approved, Investigational
ProgabideProgabide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PromestrieneThe serum concentration of Ganciclovir can be increased when it is combined with Promestriene.Investigational
PropafenoneThe serum concentration of Ganciclovir can be increased when it is combined with Propafenone.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Ganciclovir.Approved, Investigational
PropylthiouracilThe serum concentration of Ganciclovir can be increased when it is combined with Propylthiouracil.Approved, Investigational
PrulifloxacinThe metabolism of Ganciclovir can be decreased when combined with Prulifloxacin.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Ganciclovir.Approved
QuazepamThe therapeutic efficacy of Quazepam can be decreased when used in combination with Ganciclovir.Approved, Illicit
QuinestrolThe serum concentration of Ganciclovir can be increased when it is combined with Quinestrol.Approved
QuinineThe serum concentration of Ganciclovir can be increased when it is combined with Quinine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Ganciclovir.Approved
RemacemideRemacemide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
RidaforolimusThe metabolism of Ganciclovir can be decreased when combined with Ridaforolimus.Investigational
RifampicinThe metabolism of Ganciclovir can be increased when combined with Rifampicin.Approved
RiluzoleRiluzole may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
RiociguatGanciclovir may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Ganciclovir.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Ganciclovir.Approved, Investigational
RokitamycinThe metabolism of Ganciclovir can be decreased when combined with Rokitamycin.Experimental
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Ronifibrate.Experimental
RosoxacinThe metabolism of Ganciclovir can be decreased when combined with Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Rosuvastatin.Approved
RufinamideRufinamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
RufloxacinThe metabolism of Ganciclovir can be decreased when combined with Rufloxacin.Experimental
SagopiloneThe metabolism of Ganciclovir can be decreased when combined with Sagopilone.Investigational
SarafloxacinThe metabolism of Ganciclovir can be decreased when combined with Sarafloxacin.Vet Approved, Withdrawn
SecobarbitalThe serum concentration of Ganciclovir can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelamectinThe metabolism of Ganciclovir can be decreased when combined with Selamectin.Vet Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Simfibrate.Experimental
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ganciclovir is combined with Simvastatin.Approved
SirolimusThe metabolism of Ganciclovir can be decreased when combined with Sirolimus.Approved, Investigational
SitafloxacinThe metabolism of Ganciclovir can be decreased when combined with Sitafloxacin.Experimental, Investigational
Sodium iodideThe serum concentration of Ganciclovir can be increased when it is combined with Sodium iodide.Approved
SolithromycinThe metabolism of Ganciclovir can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Ganciclovir.Approved
SparfloxacinThe metabolism of Ganciclovir can be decreased when combined with Sparfloxacin.Approved, Investigational
StavudineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Stavudine.Approved, Investigational
StiripentolStiripentol may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
SulthiameSulthiame may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Ganciclovir.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Ganciclovir can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Ganciclovir can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrolimusThe metabolism of Ganciclovir can be decreased when combined with Tacrolimus.Approved, Investigational
Technetium Tc-99m ciprofloxacinThe metabolism of Ganciclovir can be decreased when combined with Technetium Tc-99m ciprofloxacin.Investigational
TemafloxacinThe metabolism of Ganciclovir can be decreased when combined with Temafloxacin.Withdrawn
TemazepamThe therapeutic efficacy of Temazepam can be decreased when used in combination with Ganciclovir.Approved, Investigational
TemsirolimusThe metabolism of Ganciclovir can be decreased when combined with Temsirolimus.Approved
Tenofovir disoproxilThe serum concentration of Tenofovir disoproxil can be increased when it is combined with Ganciclovir.Approved, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Ganciclovir.Approved
TertatololThe risk or severity of adverse effects can be increased when Tertatolol is combined with Ganciclovir.Experimental
TetracyclineThe excretion of Tetracycline can be decreased when combined with Ganciclovir.Approved, Vet Approved
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Ganciclovir.Approved
ThiabendazoleThe metabolism of Ganciclovir can be decreased when combined with Thiabendazole.Approved, Vet Approved
ThiamylalThe serum concentration of Ganciclovir can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe serum concentration of Ganciclovir can be decreased when it is combined with Thiopental.Approved, Vet Approved
Thyroid, porcineThe metabolism of Ganciclovir can be increased when combined with Thyroid, porcine.Approved
TiagabineTiagabine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TiboloneThe serum concentration of Ganciclovir can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Ganciclovir can be decreased when combined with Ticlopidine.Approved
TildipirosinThe metabolism of Ganciclovir can be decreased when combined with Tildipirosin.Vet Approved
TiletamineTiletamine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Vet Approved
TilmicosinThe metabolism of Ganciclovir can be decreased when combined with Tilmicosin.Investigational, Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Ganciclovir.Approved
TizanidineTizanidine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TofisopamThe therapeutic efficacy of Tofisopam can be decreased when used in combination with Ganciclovir.Approved
TopiramateTopiramate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
TramazolineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Ganciclovir.Investigational
TramiprosateTramiprosate may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Trastuzumab emtansineThe metabolism of Ganciclovir can be decreased when combined with Trastuzumab emtansine.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Tretoquinol is combined with Ganciclovir.Experimental
TriazolamThe therapeutic efficacy of Triazolam can be decreased when used in combination with Ganciclovir.Approved, Investigational
TrimethadioneTrimethadione may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
TroleandomycinThe metabolism of Ganciclovir can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe metabolism of Ganciclovir can be decreased when combined with Trovafloxacin.Approved, Investigational, Withdrawn
TylosinThe metabolism of Ganciclovir can be decreased when combined with Tylosin.Vet Approved
TylvalosinThe metabolism of Ganciclovir can be decreased when combined with Tylvalosin.Vet Approved
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Ganciclovir.Investigational, Nutraceutical
Valproic AcidValproic Acid may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValpromideValpromide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Experimental
VigabatrinVigabatrin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
VinpocetineVinpocetine may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Ganciclovir.Approved, Investigational
ZalcitabineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine.Approved, Investigational
ZaleplonZaleplon may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Illicit, Investigational
ZeranolThe serum concentration of Ganciclovir can be increased when it is combined with Zeranol.Vet Approved
ZidovudineThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Zidovudine.Approved
ZonisamideZonisamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Food Interactions
  • Take with food, food increases bioavailability.

References

Synthesis Reference
US4355032
General References
Not Available
External Links
Human Metabolome Database
HMDB0015139
KEGG Drug
D00333
PubChem Compound
3454
PubChem Substance
46507294
ChemSpider
3336
BindingDB
85707
ChEBI
465284
ChEMBL
CHEMBL182
Therapeutic Targets Database
DAP000645
PharmGKB
PA449733
HET
GA2
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ganciclovir
ATC Codes
R03DA20 — Combinations of xanthinesS01AD09 — GanciclovirJ05AB06 — Ganciclovir
AHFS Codes
  • 08:18.32 — Nucleosides and Nucleotides
PDB Entries
1ki2 / 4da6
FDA label
Download (489 KB)
MSDS
Download (119 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer of the Ovary1
1CompletedTreatmentColitis / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections4
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus2
1CompletedTreatmentLeukemias / Malignant Lymphomas / Precancerous Conditions / Small Intestine Cancer1
1CompletedTreatmentMelanoma (Skin)1
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Brain1
1CompletedTreatmentNeuroblastomas1
1RecruitingTreatmentTransplantation, Liver1
1TerminatedTreatmentLymphoproliferative Disorders / Malignant Lymphomas1
1Unknown StatusTreatmentMesothelioma, Malignant1
1WithdrawnTreatmentEncephalopathies / Human Immunodeficiency Virus (HIV) Infections / Radiculitis1
1, 2CompletedTreatmentInfections, Cytomegalovirus1
1, 2CompletedTreatmentKidney Diseases / Transplant, Kidney / Transplantation, Kidney / Transplantation, Renal1
2Active Not RecruitingPreventionAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Respiratory Failure1
2CompletedPreventionCritical Illness1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Smith-Magenis Syndrome1
2CompletedTreatmentCytomegalovirus Retinitis / Gastrointestinal Diseases / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections3
2CompletedTreatmentDiabetes Mellitus, Insulin-Dependent1
2CompletedTreatmentHepatocellular,Carcinoma / Liver Cancer1
2CompletedTreatmentMalignant Lymphomas2
2RecruitingTreatmentHerpes Zoster Keratitis1
2TerminatedTreatmentEBV Lymphomas / Lympho-proliferative Diseases1
2Unknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Nonneoplastic Condition1
2Unknown StatusTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2, 3Not Yet RecruitingTreatmentCytomegalovirus Anterior Uveitis1
3CompletedPreventionInfections, Cytomegalovirus1
3CompletedSupportive CareInfection NOS1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Cytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections5
3CompletedTreatmentInfections, Cytomegalovirus2
3RecruitingNot AvailableRenal Transplanted Recipients1
3TerminatedPreventionAllogeneic Stem Cell Transplantation1
3TerminatedTreatmentInfections, Cytomegalovirus1
3Unknown StatusTreatmentAdenovirus / Conjunctivitis1
4CompletedPreventionDNA Virus Infections / Infections, Cytomegalovirus / Infections, Herpesviridae1
4CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentInfections, Cytomegalovirus2
4CompletedTreatmentKeratoconjunctivitis Due to Adenovirus / Viral Shedding1
4CompletedTreatmentViral sepsis1
4RecruitingTreatmentHematological Diseases / Infections, Cytomegalovirus1
4RecruitingTreatmentViral Pneumonia1
Not AvailableCompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Acute Undifferentiated Leukemia (AUL) / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Atypical Chronic Myeloid Leukemia, BCR-ABL Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Infections, Cytomegalovirus / Intraocular Lymphoma / Isolated Plasmacytoma of Bone / Leukemia, Prolymphocytic / Malignant mast cell neoplasm / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Primary Systemic Amyloidosis / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenström's Macroglobulinemia (WM)1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Nonneoplastic Condition1
Not AvailableCompletedTreatmentAdenoviridae Infections / Conjunctivitis, Viral1
Not AvailableCompletedTreatmentAnterior Uveitis (AU) / Cytomegalovirus Anterior Segment Infection / Endotheliitis1
Not AvailableCompletedTreatmentColitis / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections11
Not AvailableCompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus4
Not AvailableCompletedTreatmentDiffuse posterior uveitis / Viral Infections1
Not AvailableRecruitingNot AvailableChildren; Infection / Newborn; Infection1
Not AvailableRecruitingTreatmentPrimary keratoconjunctivitis caused by herpes simplex virus type 21
Not AvailableUnknown StatusDiagnosticInfections, Cytomegalovirus1

Pharmacoeconomics

Manufacturers
  • Roche palo alto llc
  • Ranbaxy laboratories ltd
  • Bausch and lomb inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
Packagers
  • Alliance Medical Products
  • APP Pharmaceuticals
  • Bausch & Lomb Inc.
  • Bedford Labs
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
  • JHP Pharmaceuticals LLC
  • Physicians Total Care Inc.
  • Ranbaxy Laboratories
  • Sirion Therapeutics
Dosage forms
FormRouteStrength
CapsuleOral250 mg
Powder, for solutionIntravenous500 mg
Injection, powder, lyophilized, for solutionIntravenous500 mg/10mL
CapsuleOral500 mg
CapsuleOral250 mg/1
CapsuleOral500 mg/1
Injection, solutionIntravenous2 mg/mL
Injection, solutionIntravenous50 mg/mL
Injection, solutionIntravenous500 mg/10mL
ImplantIntravitreal4.5 mg
GelOphthalmic1.5 mg/g
Prices
Unit descriptionCostUnit
Vitrasert 4.5 mg implant19200.0USD implant
Cytovene 500 mg vial81.06USD vial
Cytovene 500 mg/vial46.41USD vial
Zirgan 0.15% ophthalmic gel33.6USD g
Ganciclovir 500 mg capsule19.66USD capsule
Cytovene 500 mg capsule10.99USD capsule
Cytovene 250 mg capsule5.61USD capsule
Ganciclovir 250 mg capsule4.72USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5378475No1995-01-032012-01-03Us
US9486530No2014-09-022034-09-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)250 dec °CPhysProp
water solubility4300 mg/L (at 25 °C)MERCK INDEX (1996); pH 7
logP-1.66SANGSTER (1993)
Caco2 permeability-6.27ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility11.5 mg/mLALOGPS
logP-1.8ALOGPS
logP-2.2ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)10.16ChemAxon
pKa (Strongest Basic)1.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area134.99 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity61.03 m3·mol-1ChemAxon
Polarizability24.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9443
Blood Brain Barrier+0.9866
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.5767
P-glycoprotein inhibitor INon-inhibitor0.932
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8459
CYP450 2C9 substrateNon-substrate0.8907
CYP450 2D6 substrateNon-substrate0.8225
CYP450 3A4 substrateNon-substrate0.5919
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.96
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.935
Ames testNon AMES toxic0.6094
CarcinogenicityNon-carcinogens0.8875
BiodegradationNot ready biodegradable0.9368
Rat acute toxicity2.0348 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9611
hERG inhibition (predictor II)Non-inhibitor0.8943
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0gb9-0090000000-b4bf1558f31e6cd80503
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-1090000000-80a7b4d22e1375eb8a4d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000j-9610000000-c3053bd735d9f92930bf
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-007a-9300000000-392c976e03c2a82984cc
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-9000000000-168468ed262e2df62267
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4r-0490000000-0a16ac79577fd707fd15
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0920000000-16d50b83e7be32f4db70
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-1900000000-2eca31ed3c60988970dc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udu-2900000000-fd85740333fbb29714c8
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01pc-3900000000-81b422bf6764161bcb0f
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0udi-0900000000-618946bbba03bdf5db19

Taxonomy

Description
This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Hypoxanthines
Alternative Parents
6-oxopurines / Pyrimidones / Glycerolipids / Aminopyrimidines and derivatives / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Primary alcohols
show 3 more
Substituents
6-oxopurine / Hypoxanthine / Aminopyrimidine / Pyrimidone / Glycerolipid / N-substituted imidazole / Pyrimidine / Azole / Imidazole / Heteroaromatic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
oxopurine, 2-aminopurines (CHEBI:465284)

Targets

Kind
Protein
Organism
HHV-1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding pro...
Gene Name
Not Available
Uniprot ID
P04293
Uniprot Name
DNA polymerase catalytic subunit
Molecular Weight
136419.66 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Boivin G, Goyette N, Gilbert C, Covington E: Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol. 2005 Nov;77(3):425-9. [PubMed:16173018]
  4. Wang JT, Yang PW, Lee CP, Han CH, Tsai CH, Chen MR: Detection of Epstein-Barr virus BGLF4 protein kinase in virus replication compartments and virus particles. J Gen Virol. 2005 Dec;86(Pt 12):3215-25. [PubMed:16298966]
  5. Shi R, Azzi A, Gilbert C, Boivin G, Lin SX: Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins. 2006 Aug 1;64(2):301-7. [PubMed:16705640]
2. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Incorporation into and destabilization
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Martin M, Azzi A, Lin SX, Boivin G: Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. Antivir Ther. 2010;15(4):579-86. doi: 10.3851/IMP1565. [PubMed:20587851]
  2. Boivin G, Goyette N, Gilbert C, Covington E: Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol. 2005 Nov;77(3):425-9. [PubMed:16173018]
  3. Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL: Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol. 2007 Feb;38(2):120-5. Epub 2006 Dec 8. [PubMed:17157554]
  4. Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA: Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006 Aug 15;82(3):398-405. [PubMed:16906040]
Kind
Protein
Organism
HHV-1
Pharmacological action
Yes
Actions
Inducer
General Function
Thymidine kinase activity
Specific Function
In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate the...
Gene Name
TK
Uniprot ID
P03176
Uniprot Name
Thymidine kinase
Molecular Weight
40971.555 Da
References
  1. Champness JN, Bennett MS, Wien F, Visse R, Summers WC, Herdewijn P, de Clerq E, Ostrowski T, Jarvest RL, Sanderson MR: Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins. 1998 Aug 15;32(3):350-61. [PubMed:9715911]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Saito Y, Hanioka N, Maekawa K, Isobe T, Tsuneto Y, Nakamura R, Soyama A, Ozawa S, Tanaka-Kagawa T, Jinno H, Narimatsu S, Sawada J: Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos. 2005 Dec;33(12):1905-10. Epub 2005 Sep 20. [PubMed:16174806]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:47